Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Takeda Pharmaceutical Co. (TAK) vs Teva Pharmaceutical Industries Ltd. (TEVA)

Takeda Pharmaceutical Co. and Teva Pharmaceutical Industries Ltd. are both Drug Manufacturers Specialty & Generic companies. Takeda Pharmaceutical Co. is the larger, with a market value of $59.2B against $46.9B — 1.3× the size. Takeda Pharmaceutical Co. trades at the lower P/E: 28.4× against 62.2×. Teva Pharmaceutical Industries Ltd. grew revenue faster over the last twelve months: 4.13% against 0.66%. Takeda Pharmaceutical Co. has the higher net margin (7.12% vs 4.08%) and the lower return on invested capital (2.88% vs 4.58%). Across the 21 metrics below, Takeda Pharmaceutical Co. leads on 15 and Teva Pharmaceutical Industries Ltd. on 6.

Valuation

Metric TAK TEVA Drug Manufacturers Specialty & Generic median
P/E 28.36 62.21 20.14
P/S 1.99 2.64 2.25
P/B 1.25 5.89 1.90
Price to free cash flow 8.03 32.59 16.54
EV/EBITDA 10.48 23.38 12.29
EV/Sales 2.91 3.38 2.56
Earnings yield 3.53% 1.61% (2.99%)
Free cash flow yield 12.46% 3.07% 0.00%

Profitability

Metric TAK TEVA Drug Manufacturers Specialty & Generic median
Gross margin 65.85% 52.46% 53.94%
Operating margin 11.61% 8.77% 0.00%
Net margin 7.12% 4.08% 0.00%
Free cash flow margin 24.74% 8.09% 0.00%
Return on equity 4.42% 9.69% (0.40%)
Return on assets 2.15% 1.77% (3.32%)
Return on invested capital 2.88% 4.58% 0.00%

Growth

Metric TAK TEVA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 0.66% 4.13% 10.01%
EPS growth (last fiscal year) (244.86%) 183.45% —
Revenue growth, 5-year CAGR (0.21%) 0.71% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TAK TEVA Drug Manufacturers Specialty & Generic median
Debt to equity 0.65 2.14 0.05
Current ratio 1.14 0.88 2.31
Net debt to EBITDA 5.84 4.19 0.85

Dividend

Metric TAK TEVA Drug Manufacturers Specialty & Generic median
Dividend yield 4.52% — 1.70%
Payout ratio 0.50 0.00 0.00

Size

Metric TAK TEVA Drug Manufacturers Specialty & Generic median
Market cap 59.16b 46.87b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack